BC Week In Review | Jul 13, 2017
Company News

ADC Therapuetics options one Chiome antibody, declines another

Chiome Bioscience Inc. (Tokyo:4583) said it received notification from ADC Therapeutics S.A. (Epalinges, Switzerland) that ADC intends to exercise its option to negotiate rights to LIV-1205 . The exclusive, worldwide rights would cover the development and...
BC Week In Review | Apr 11, 2016
Company News

Chiome, ADC Therapeutics deal

Chiome granted ADC a right to evaluate LIV-2008b and an option to license exclusive, worldwide rights to develop LIV-2008b as an antibody-drug conjugate (ADC) to treat cancer. Chiome is eligible to receive up to Y11...
BC Week In Review | Aug 3, 2015
Company News

Chiome, ADC Therapeutics deal

Chiome’s LivTech Inc. subsidiary granted ADC an option for exclusive, worldwide rights to develop LIV-1205 as an antibody-drug conjugate (ADC) to treat cancer. Upon exercise, LivTech will receive an undisclosed upfront payment and is eligible...
BioCentury | Apr 6, 2015
Finance

Up, up and acquired

For the first time since 1Q14, none of the biotech market cap segments fell. While the $200-$499 million tier treaded water, all other segments finished in the black, led by the $1-$4.9 billion segment. Large...
BioCentury | Feb 23, 2015
Finance

Daiwa dives in

The Daiwa Corporate Investment Co. Ltd. private equity arm of Daiwa Securities Group has for years made one-off investments in biotechs from its general funds. But the group decided a favorable investment climate for biotechs...
BC Week In Review | Mar 24, 2014
Company News

Chiome antibodies news

Chiome said it constructed and verified a DT40 cell line for the human ADLib (Autonomously Diversifying Library) system to generate mAbs in vitro. Chiome said it developed a DT40 cell line for a prototype human...
BioCentury | Mar 24, 2014
Finance

Highlights of weekly biotech stock moves

Regulatory milestones AB Science S.A. (Euronext:AB) fell €1.61 (11%) to €12.67 on Friday after EMA's CHMP again recommended against conditional approval of masitinib for second-line treatment of gastrointestinal stromal tumors. AB Science was appealing a...
BioCentury | Feb 10, 2014
Finance

A Japanese correction

A Japanese correction Japan's biotechs exhibited the high beta typical of the sector last week, falling more than five times as much as the country's broader markets, which themselves have been taking a beating. Nevertheless,...
BC Week In Review | Jul 1, 2013
Company News

Chiome antibodies news

Chiome said it developed a DT40 cell line for the prototype human ADLib system to generate mAbs in vitro. Before launching the ADLib (Autonomously Diversifying Library) system, Chiome said it needs to diversify selected clones...
BioCentury | Jun 17, 2013
Finance

Living the dream

PeptiDream Inc. (Tokyo:4587) jumped over 400% in its first week of trading, but due to rules on daily price limits, there's no telling what investors are really willing to pay for the company. The preclinical...
Items per page:
1 - 10 of 37
BC Week In Review | Jul 13, 2017
Company News

ADC Therapuetics options one Chiome antibody, declines another

Chiome Bioscience Inc. (Tokyo:4583) said it received notification from ADC Therapeutics S.A. (Epalinges, Switzerland) that ADC intends to exercise its option to negotiate rights to LIV-1205 . The exclusive, worldwide rights would cover the development and...
BC Week In Review | Apr 11, 2016
Company News

Chiome, ADC Therapeutics deal

Chiome granted ADC a right to evaluate LIV-2008b and an option to license exclusive, worldwide rights to develop LIV-2008b as an antibody-drug conjugate (ADC) to treat cancer. Chiome is eligible to receive up to Y11...
BC Week In Review | Aug 3, 2015
Company News

Chiome, ADC Therapeutics deal

Chiome’s LivTech Inc. subsidiary granted ADC an option for exclusive, worldwide rights to develop LIV-1205 as an antibody-drug conjugate (ADC) to treat cancer. Upon exercise, LivTech will receive an undisclosed upfront payment and is eligible...
BioCentury | Apr 6, 2015
Finance

Up, up and acquired

For the first time since 1Q14, none of the biotech market cap segments fell. While the $200-$499 million tier treaded water, all other segments finished in the black, led by the $1-$4.9 billion segment. Large...
BioCentury | Feb 23, 2015
Finance

Daiwa dives in

The Daiwa Corporate Investment Co. Ltd. private equity arm of Daiwa Securities Group has for years made one-off investments in biotechs from its general funds. But the group decided a favorable investment climate for biotechs...
BC Week In Review | Mar 24, 2014
Company News

Chiome antibodies news

Chiome said it constructed and verified a DT40 cell line for the human ADLib (Autonomously Diversifying Library) system to generate mAbs in vitro. Chiome said it developed a DT40 cell line for a prototype human...
BioCentury | Mar 24, 2014
Finance

Highlights of weekly biotech stock moves

Regulatory milestones AB Science S.A. (Euronext:AB) fell €1.61 (11%) to €12.67 on Friday after EMA's CHMP again recommended against conditional approval of masitinib for second-line treatment of gastrointestinal stromal tumors. AB Science was appealing a...
BioCentury | Feb 10, 2014
Finance

A Japanese correction

A Japanese correction Japan's biotechs exhibited the high beta typical of the sector last week, falling more than five times as much as the country's broader markets, which themselves have been taking a beating. Nevertheless,...
BC Week In Review | Jul 1, 2013
Company News

Chiome antibodies news

Chiome said it developed a DT40 cell line for the prototype human ADLib system to generate mAbs in vitro. Before launching the ADLib (Autonomously Diversifying Library) system, Chiome said it needs to diversify selected clones...
BioCentury | Jun 17, 2013
Finance

Living the dream

PeptiDream Inc. (Tokyo:4587) jumped over 400% in its first week of trading, but due to rules on daily price limits, there's no telling what investors are really willing to pay for the company. The preclinical...
Items per page:
1 - 10 of 37